Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years

The Shandong Provincial Center for Disease Control and Prevention, China

The goal of this [To evaluate the immunogenicity and safety of 1 - and 2-dose schedules of quadrivalent influenza vaccine (split virion) in healthy people with and without immunization history.] is to [aged 3-8 years] in [Healthy people]. The main question[s] it aims to answer are: • [To evaluate the immunogenicity of a two-dose schedule of quadrivalent influenza vaccine (quadrivalent influenza vaccine) in healthy population aged 3-8 years with or without vaccination history.]

•[ To evaluate whether antibody levels are different 30 days after one dose of quadrivalent influenza vaccine versus two doses of quadrivalent influenza vaccine in healthy people aged 3-8 years with or without vaccination history.]

Study Overview

• Status: Completed
• Conditions: GCP
• Intervention / Treatment: Biological: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Detailed Description

An open clinical trial design was used. A total of 652 healthy children aged 3-8 years, 326 with vaccination history and 326 without vaccination history, were selected to receive two doses of normal commercially available quadrivalent influenza vaccine according to a 0 -, 30-day schedule.

Immunogenicity: blood samples were collected for HI antibody detection before the first dose of influenza vaccine (before immunization), 30 days after the first dose of influenza vaccine (before the second dose of influenza vaccine) and 30 days after the second dose of influenza vaccine.

Adverse events (AE) were observed 30 minutes, 0-7 days and 8-30 days after each dose of vaccination by active follow-up combined with guardian reports. Occurrence of SAEs between 31 and 180 days after the second dose of vaccine.

Criteria for evaluation of immunogenicity According to the European Union seasonal influenza evaluation criteria, if the HI antibody seroconversion rate of each subtype of influenza virus was ≥40%, the HI antibody positive rate was ≥70%, and the GMI of each subtype of influenza virus was ≥2.5 times 30 days after any dose of vaccination, the vaccination schedule was considered to have acceptable immunogenicity.

Safety outcome MEASURES The occurrence of adverse reactions/events after each dose of vaccination was observed. The incidence of ① total adverse reactions/events, ② incidence of grade 3 or above adverse reactions/events and SAE, ③ incidence of adverse reactions/events severity classification, ④ incidence of adverse reactions/events by type (inoculation site and systemic, SOC, PT) and incidence of adverse reactions/events severity classification were calculated.

Note: Known adverse effects of quadrivalent influenza vaccine that have been identified in previous clinical studies are as follows:

Inoculation site (local) adverse events: pain, induration, swelling, rash, redness, pruritus, cellulitis.

Adverse events at non-inoculated sites (systemic) included fever, diarrhea, constipation, dysphagia, anorexia, vomiting, nausea, myalgia (non-inoculated sites), arthralgia, headache, cough, dyspnea, pruritus at non-inoculated sites (without skin lesions), mucocutaneous abnormalities, irritation/inhibition, acute anaphylaxis, and fatigue/fatigue.

• Study Type: Observational
• Enrollment (Actual): 652

Contacts and Locations

Study Locations

• China
  • Shandong
    • Jinan, Shandong, China, 250000
      • Kou Zengqiang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Healthy people aged 3-8 years old

Description

Inclusion Criteria:

• 3-8 years old;
• The legal guardian / authorized agent gives the informed consent and voluntarily signs the informed consent to comply with the requirements of the clinical trial protocol;
• Medical history, physical examination and clinical diagnosis, who to the immunization of this product.
• children who have received two or more doses of influenza vaccine (4 weeks apart) before the season of this influenza epidemic (2 doses of influenza vaccine do not need to be vaccinated in the same epidemic season or consecutive epidemic season, but can be interpreted as children who have received two or more cumulative shots).

History of l No immunization: children who had not been vaccinated or had previously received <2 doses of influenza vaccine before the influenza season.

Exclusion Criteria:

1.1.1The exclusion criteria for the first needle To l allergic to any component of the quadrialent influenza vaccine (history of any previous vaccine allergy), especially those allergic to eggs; The l axillary body temperature was 37.5℃ before inoculation;

• Any influenza vaccine (registered or research) within 6 months prior to enrollment; or planned for use during the study period;
• Use of immunoglobulin and / or any blood products within 3 months prior to enrollment; or planned for use during the study (before blood sampling);
• Patients with a history of Guillain-Barre syndrome; l Acute disease, severe chronic disease, acute onset of chronic disease, cold;
• Uncontrolled epilepsy;
• Has been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, or other autoimmune diseases;
• those receiving immune booster or inhibitor treatment within 3 months (continuous oral or drip for more than 14 days);
• History of abnormal coagulation function (such as lack of coagulation factors, coagulation disease);
• Primary and secondary impaired immunity (history of thyroid, pancreas, liver and spleen resection);
• A history of severe allergic reactions to vaccination;
• live attenuated vaccine within 14 days before vaccination and other vaccines within 7 days before vaccination;
• Is in or recently planning to participate in other clinical trials;
• Other conditions judged by the investigator as not suitable for participation in this clinical trial.

1.1.2 Exclusion criteria for the second needle

• Patients with severe allergic reactions after the previous dose of vaccination;
• Serious adverse reactions with a causal relationship with the previous dose of vaccination; l For newly detected or those who do not meet the inclusion criteria of the first injection or meet the exclusion criteria of the first injection, the investigator will determine whether to continue to participate in the study;
• Other reasons for exclusion as considered by the investigator.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
There was an immunological history group; l Children who have received two or more doses of influenza vaccine (4 weeks apart) before the influenza season (2 doses of influenza vaccine do not need to be administered in the same epidemic season or consecutive epidemic season, and can be interpreted as children who have received two or more cumulative doses).	Biological: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent; A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.
There was no immunological history group; l Children who have not received or previously received <2 doses of influenza vaccine before the epidemic season.	Biological: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent; A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
evaluate the immunogenicity of 1-dose and 2-dose schedule in 3-8 years old healthy people with and without immunization history	The lower limit of the 95% confidence interval (CI) of the seroconversion rate (SCR) of hemagglutination inhibition (HAI) antibodies against each virus strain after vaccination was ≥40%. The lowest dilution used in the assay was 1 in 10. Seroconversion was defined as a prevaccination HAI titer of <1:10 and a postvaccination titer of ≥1:40 or a prevaccination titer of ≥1:10 and a 4-fold or greater increase in titer after vaccination.	Blood samples were collected before immunization, 30 days after the first dose (before the second dose) and 30 days after the first dose for influenza virus HI antibodies.
evaluate the safety of one dose and two doses schedule in children aged 3-8 years	The occurrence of adverse reactions/events after each dose of vaccination was observed. The incidence of ① total adverse reactions/events, ② incidence of grade 3 or above adverse reactions/events and SAE, ③ incidence of adverse reactions/events severity classification, ④ incidence of adverse reactions/events by type (inoculation site and systemic, SOC, PT) and incidence of adverse reactions/events severity classification were calculated.	The safety was observed until 6 months after the full course of immunization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Differences in antibody levels 30 days after one dose and two doses of quadrivalent influenza vaccine among healthy people aged 3-8 years with or without vaccination history.	Seroconversion rate, positive rate, GMT and GMI of HI antibody against each subtype of influenza virus were calculated 30 days after the first dose and 30 days after the second dose in the vaccination history group and non-vaccination history group, respectively. The Clopper-Pearson exact probability method was used to calculate confidence intervals for rates.	Blood samples were collected before immunization, 30 days after the first dose (before the second dose) and 30 days after the first dose for influenza virus HI antibodies.

Collaborators and Investigators

• Sponsor: Hualan Biological Bacterin Co. Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 15, 2021
• Primary Completion (Actual): February 6, 2023
• Study Completion (Actual): February 28, 2023

Study Registration Dates

• First Submitted: September 25, 2023
• First Submitted That Met QC Criteria: October 17, 2023
• First Posted (Actual): October 23, 2023

Study Record Updates

• Last Update Posted (Estimated): September 15, 2025
• Last Update Submitted That Met QC Criteria: September 8, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Biological Products; Complex Mixtures; Vaccines; Viral Vaccines; Influenza Vaccines
• Other Study ID Numbers: HL-SJLG-2021-Ⅳ-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No